The biopharma funding surge in early 2025 reflects a broader pattern of investor confidence in high-risk, high-reward therapeutic innovation, particularly in oncology, metabolic disorders, and neurodegenerative diseases. The strongest version of this narrative highlights genuine scientific progress—AI-driven drug discovery, novel delivery platforms, and targeted therapies addressing unmet medical needs. However, the sheer volume of funding raises questions about potential overvaluation and the s...